Clenbuterol Therapy for Amyotrophic Lateral Sclerosis

Unmet Need

Amyotrophic lateral sclerosis (ALS) is a debilitating disease with progressive loss of muscle function and inevitable death usually in 3-5 years. There are currently two available therapies on the market which prolong life but do not adequately treat loss of muscle function or neurological function.

Technology

This invention provides a novel repurpose of the beta-2 adrenomimetic clenbuterol for use in ALS patients.

Advantages

This therapy has already been used in asthma patients as a bronchodilator and has shown efficacy in other muscle conditions such as Pompe disease

• In preclinical studies it has shown efficacy as an ALS treatment with decreased mortality and increased muscular function
• A small clinical trial performed has also shown efficacy in ALS